New perspectives on the use of mTOR inhibitors in allogeneic haematopoietic stem cell transplantation and graft-versus-host disease

British Journal of Clinical Pharmacology

Volumn , Issue , 2016, Pages 1171-1179

  Lutz, Mathias ^a   Mielke, Stephan ^b  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

allogeneic haematopoietic stem cell transplantation; everolimus; graft versus host disease; mTOR inhibitors; sirolimus

Indexed keywords

BORTEZOMIB; CALCINEURIN INHIBITOR; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METHOTREXATE; MYCOPHENOLATE MOFETIL; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CHRONIC GRAFT VERSUS HOST DISEASE; DRUG EFFICACY; DRUG STRUCTURE; DRUG USE; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; PATIENT SAFETY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

EID: 84991267968     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.13022     Document Type: Review

References (74)

1. Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011; 12: 21–35.
2. Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol 2010; 28: 1075–83.
3. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007; 12: 9–22.
4. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006; 124: 471–84.
5. Wazir U, Wazir A, Khanzada ZS, Jiang WG, Sharma AK, Mokbel K. Current state of mTOR targeting in human breast cancer. Cancer Genomics Proteomics 2014; 11: 167–74.
6. Lee JJ, Loh K, Yap YS. PI3K/Akt/mTOR inhibitors in breast cancer. Cancer Biol Med 2015; 12: 342–54.
7. Weber HC. Medical treatment of neuroendocrine tumours. Curr Opin Endocrinol Diabetes Obes 2013; 20: 27–31.
8. Chan J, Kulke M. Targeting the mTOR signaling pathway in neuroendocrine tumors. Curr Treat Options Oncol 2014; 15: 365–79.
9. Czarnecka AM, Kornakiewicz A, Lian F, Szczylik C. Future perspectives for mTOR inhibitors in renal cell cancer treatment. Future Oncol 2015; 11: 801–17.
10. Barthelemy P, Hoch B, Chevreau C, Joly F, Laguerre B, Lokiec F, et al. mTOR inhibitors in advanced renal cell carcinomas: from biology to clinical practice. Crit Rev Oncol Hematol 2013; 88: 42–56.
11. Zeng H, Chi H. mTOR and lymphocyte metabolism. Curr Opin Immunol 2013; 25: 347–55.
12. Waickman AT, Powell JD. mTOR, metabolism, and the regulation of T-cell differentiation and function. Immunol Rev 2012; 249: 43–58.
13. Andreassen AK, Andersson B, Gustafsson F, Eiskjaer H, Radegran G, Gude E, et al. Everolimus initiation and early calcineurin inhibitor withdrawal in heart transplant recipients: a randomized trial. Am J Transplant 2014; 14: 1828–38.
14. Moes DJ, Guchelaar HJ, de Fijter JW. Sirolimus and everolimus in kidney transplantation. Drug Discov Today 2015; 20: 1243–9.
15. Klintmalm GB, Nashan B. The role of mTOR inhibitors in liver transplantation: Reviewing the evidence. J Transplant 2014; 2014: 845438.
16. Ziakas PD, Zervou FN, Zacharioudakis IM, Mylonakis E. Graft-versus-host disease prophylaxis after transplantation: a network meta-analysis. PLoS One 2014; 9: e114735.
17. Abouelnasr A, Roy J, Cohen S, Kiss T, Lachance S. Defining the role of sirolimus in the management of graft-versus-host disease: from prophylaxis to treatment. Biol Blood Marrow Transplant 2013; 19: 12–21.
18. ClinicalTrials.gov. Registered trials as of March 2016. (last accessed 1 March 2016).
19. Schuler W, Sedrani R, Cottens S, Haberlin B, Schulz M, Schuurman HJ, et al. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 1997; 64: 36–42.
20. Blazar BR, Taylor PA, Panoskaltsis-Mortari A, Sehgal S, Vallera DA. In vivo inhibition of cytokine responsiveness and graft-versus-host disease mortality by rapamycin leads to a clinical-pathological syndrome discrete from that observed with cyclosporin A. Blood 1996; 87: 4001–9.
21. Antin JH, Kim HT, Cutler C, Ho VT, Lee SJ, Miklos DB, et al. Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation. Blood 2003; 102: 1601–5.
22. Pidala J, Kim J, Jim H, Kharfan-Dabaja MA, Nishihori T, Fernandez HF, et al. A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation. Haematologica 2012; 97: 1882–9.
23. Pidala J, Kim J, Alsina M, Ayala E, Betts BC, Fernandez HF, et al. Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versus-host disease. Haematologica 2015; 100: 970–7.
24. Jim HS, Barata A, Small BJ, Jacobsen PB, Pidala J. Quality of life associated with sirolimus for prevention of graft-versus-host disease: results from a randomized trial. Haematologica 2014; 99: 548–53.
25. Cutler C, Logan B, Nakamura R, Johnston L, Choi S, Porter D, et al. Tacrolimus/sirolimus vs. tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT. Blood 2014; 124: 1372–7.
26. Pulsipher MA, Langholz B, Wall DA, Schultz KR, Bunin N, Carroll WL, et al. The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children's Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial. Blood 2014; 123: 2017–25.
27. Kornblit B, Maloney DG, Storer BE, Maris MB, Vindelov L, Hari P, et al. A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation. Haematologica 2014; 99: 1624–31.
28. Marty FM, Bryar J, Browne SK, Schwarzberg T, Ho VT, Bassett IV, et al. Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis. Blood 2007; 110: 490–500.
29. Ozaki KS, Camara NO, Nogueira E, Pereira MG, Granato C, Melaragno C, et al. The use of sirolimus in ganciclovir-resistant cytomegalovirus infections in renal transplant recipients. Clin Transplant 2007; 21: 675–80.
30. Armand P, Kim HT, Sainvil MM, Lange PB, Giardino AA, Bachanova V, et al. The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial. Br J Haematol 2016; 173: 96–104.
31. Ceberio I, Devlin SM, Sauter C, Barker JN, Castro-Malaspina H, Giralt S, et al. Sirolimus, tacrolimus and low-dose methotrexate based graft-versus-host disease prophylaxis after non-ablative or reduced intensity conditioning in related and unrelated donor allogeneic hematopoietic cell transplant. Leuk Lymphoma 2015; 56: 663–70.
32. Parody R, Lopez-Corral L, Godino OL, Cadenas IG, Martinez AP, Vazquez L, et al. GVHD prophylaxis with sirolimus-tacrolimus may overcome the deleterious effect on survival of HLA mismatch after reduced-intensity conditioning allo-SCT. Bone Marrow Transplant 2015; 50: 121–6.
33. Schleuning M, Judith D, Jedlickova Z, Stubig T, Heshmat M, Baurmann H, et al. Calcineurin inhibitor-free GVHD prophylaxis with sirolimus, mycophenolate mofetil and ATG in Allo-SCT for leukemia patients with high relapse risk: an observational cohort study. Bone Marrow Transplant 2009; 43: 717–23.
34. Johnston L, Florek M, Armstrong R, McCune JS, Arai S, Brown J, et al. Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation. Bone Marrow Transplant 2012; 47: 581–8.
35. Solomon SR, Sanacore M, Zhang X, Brown S, Holland K, Morris LE, et al. Calcineurin inhibitor–free graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and brief-course sirolimus following reduced-intensity peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2014; 20: 1828–34.
36. Cieri N, Greco R, Crucitti L, Morelli M, Giglio F, Levati G, et al. Post-transplantation Cyclophosphamide and sirolimus after haploidentical hematopoietic stem cell transplantation using a treosulfan-based myeloablative conditioning and peripheral blood stem cells. Biol Blood Marrow Transplant 2015; 21: 1506–14.
37. Caballero-Velazquez T, Sanchez-Abarca LI, Gutierrez-Cosio S, Blanco B, Calderon C, Herrero C, et al. The novel combination of sirolimus and bortezomib prevents graft-versus-host disease but maintains the graft-versus-leukemia effect after allogeneic transplantation. Haematologica 2012; 97: 1329–37.
38. Platzbecker U, von Bonin M, Goekkurt E, Radke J, Binder M, Kiani A, et al. Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial. Biol Blood Marrow Transplant 2009; 15: 101–8.
39. Junghanss C, Rathsack S, Wacke R, Weirich V, Vogel H, Drewelow B, et al. Everolimus in combination with cyclosporin a as pre- and post-transplantation immunosuppressive therapy in nonmyeloablative allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2012; 18: 1061–8.
40. Machka C, Lange S, Werner J, Wacke R, Killian D, Knueppel A, et al. Everolimus in combination with mycophenolate mofetil as pre- and post-transplantation immunosuppression after nonmyeloablative hematopoietic stem cell transplantation in canine littermates. Biol Blood Marrow Transplant 2014; 20: 1301–6.
41. Wu Q, Marescaux C, Wolff V, Jeung MY, Kessler R, Lauer V, et al. Tacrolimus-associated posterior reversible encephalopathy syndrome after solid organ transplantation. Eur Neurol 2010; 64: 169–77.
42. Schmidt V, Prell T, Treschl A, Klink A, Hochhaus A, Sayer HG. Clinical Management of Posterior Reversible Encephalopathy Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation: A Case Series and Review of the Literature. Acta Haematol 2016; 135: 1–10.
43. Pidala J, Kim J, Anasetti C. Sirolimus as primary treatment of acute graft-versus-host disease following allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2009; 15: 881–5.
44. Pidala J, Tomblyn M, Nishihori T, Field T, Ayala E, Perkins J, et al. Sirolimus demonstrates activity in the primary therapy of acute graft-versus-host disease without systemic glucocorticoids. Haematologica 2011; 96: 1351–6.
45. Benito AI, Furlong T, Martin PJ, Anasetti C, Appelbaum FR, Doney K, et al. Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. Transplantation 2001; 72: 1924–9.
46. Hoda D, Pidala J, Salgado-Vila N, Kim J, Perkins J, Bookout R, et al. Sirolimus for treatment of steroid-refractory acute graft-versus-host disease. Bone Marrow Transplant 2010; 45: 1347–51.
47. Ghez D, Rubio MT, Maillard N, Suarez F, Chandesris MO, Delarue R, et al. Rapamycin for refractory acute graft-versus-host disease. Transplantation 2009; 88: 1081–7.
48. Salas-Prato M, Assalian A, Mehdi AZ, Duperre J, Thompson P, Brazeau P. Inhibition by rapamycin of PDGF- and bFGF-induced human tenon fibroblast proliferation in vitro. J Glaucoma 1996; 5: 54–9.
49. Namba DR, Ma G, Samad I, Ding D, Pandian V, Powell JD, et al. Rapamycin inhibits human laryngotracheal stenosis-derived fibroblast proliferation, metabolism, and function in vitro. Otolaryngol Head Neck Surg 2015; 152: 881–8.
50. Gratwohl AA, Moutsopoulos HM, Chused TM, Akizuki M, Wolf RO, Sweet JB, et al. Sjogren-type syndrome after allogeneic bone-marrow transplantation. Ann Intern Med 1977; 87: 703–6.
51. Shao L, Lie AK, Zhang Y, Wong CH, Kwong YL. Aberrant germinal center formation, follicular T-helper cells, and germinal center B-cells were involved in chronic graft-versus-host disease. Ann Hematol 2015; 94: 1493–504.
52. Johnston LJ, Brown J, Shizuru JA, Stockerl-Goldstein KE, Stuart MJ, Blume KG, et al. Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2005; 11: 47–55.
53. Couriel DR, Saliba R, Escalon MP, Hsu Y, Ghosh S, Ippoliti C, et al. Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease. Br J Haematol 2005; 130: 409–17.
54. Jurado M, Vallejo C, Perez-Simon JA, Brunet S, Ferra C, Balsalobre P, et al. Sirolimus as part of immunosuppressive therapy for refractory chronic graft-versus-host disease. Biol Blood Marrow Transplant 2007; 13: 701–6.
55. Jedlickova Z, Burlakova I, Bug G, Baurmann H, Schwerdtfeger R, Schleuning M. Therapy of sclerodermatous chronic graft-versus-host disease with mammalian target of rapamycin inhibitors. Biol Blood Marrow Transplant 2011; 17: 657–63.
56. Garcia-Martin P, Alarcon-Payer C, Lopez-Fernandez E, Moratalla L, Romero A, Sainz J, et al. Transplantation-associated thrombotic microangiopathy in patients treated with sirolimus and cyclosporine as salvage therapy for graft-versus-host disease. Ann Pharmacother 2015; 49: 986–94.
57. Wolff D, Schleuning M, von Harsdorf S, Bacher U, Gerbitz A, Stadler M, et al. Consensus Conference on Clinical Practice in Chronic GVHD: Second-line treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2011; 17: 1–17.
58. Schleuning M. Systemic treatment of chronic GVHD. Cell Ther Transplant 2009; 2: e.000050.01. doi:10.3205/ctt-2009-en-000050.01.
59. Klink A, Schilling K, Rapp K, Höffken K, Sayer HG. High overall response rate in calcineurin inhibitor-free treatment with the mTOR inhibitor everolimus in advanced extensive chronic GvHD after allogeneic stem cell transplantation. Blood (ASH Annual Meeting Abstracts) 2008; 112: 2210.
60. Brown A, Neumayer D, Rafiee-Tari Z, Krieg T, Eming SA. [Delayed wound healing during therapy of cutaneous graft-versus-host disease with everolimus]. Hautarzt 2014; 65: 553–5.
61. Ferte C, Paci A, Zizi M, Gonzales DB, Goubar A, Gomez-Roca C, et al. Natural history, management and pharmacokinetics of everolimus-induced-oral ulcers: insights into compliance issues. Eur J Cancer 2011; 47: 2249–55.
62. Mielke S, Lutz M, Schmidhuber J, Kapp M, Ditz D, Ammer J, et al. Salvage therapy with everolimus reduces the severity of treatment-refractory chronic GVHD without impairing disease control: a dual center retrospective analysis. Bone Marrow Transplant 2014; 49: 1412–8.
63. Armand P, Gannamaneni S, Kim HT, Cutler CS, Ho VT, Koreth J, et al. Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning. J Clin Oncol 2008; 26: 5767–74.
64. Recher C, Beyne-Rauzy O, Demur C, Chicanne G, Dos Santos C, Mas VM, et al. Antileukemic activity of rapamycin in acute myeloid leukemia. Blood 2005; 105: 2527–34.
65. Lutz M, Kapp M, Einsele H, Grigoleit GU, Mielke S. Improvement of quality of life in patients with steroid-refractory chronic graft-versus-host disease treated with the mTOR inhibitor everolimus. Clin Transplant 2014; 28: 1410–5.
66. Hefner J, Kapp M, Drebinger K, Dannenmann A, Einsele H, Grigoleit GU, et al. High prevalence of distress in patients after allogeneic hematopoietic SCT: fear of progression is associated with a younger age. Bone Marrow Transplant 2014; 49: 581–4.
67. Dignan FL, Manwani R, Potter MN, Ethell ME, Leonard H, Brennan J, et al. A dedicated GvHD clinic may improve the quality of life for allogeneic stem cell transplant survivors. Clin Transplant 2013; 27: E1–2.
68. Wood WA, Chai X, Weisdorf D, Martin PJ, Cutler C, Inamoto Y, et al. Comorbidity burden in patients with chronic GVHD. Bone Marrow Transplant 2013; 48: 1429–36.
69. ClincalTrials.gov. Treatment of newly diagnosed moderate or severe chronic graft-versus-host disease with prednisone and everolimus (PredEver first). Identifier: NCT01862965. (last accessed 1 March 2016).
70. Zeiser R, Burchert A, Lengerke C, Verbeek M, Maas-Bauer K, Metzelder SK, et al. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia 2015; 29: 2062–8.
71. Emoto C, Fukuda T, Venkatasubramanian R, Vinks AA. The impact of CYP3A5*3 polymorphism on sirolimus pharmacokinetics: insights from predictions with a physiologically-based pharmacokinetic model. Br J Clin Pharmacol 2015; 80: 1438–46.
72. Klawitter J, Nashan B, Christians U. Everolimus and sirolimus in transplantation-related but different. Expert Opin Drug Saf 2015; 14: 1055–70.
73. Grabowsky JA. Drug interactions and the pharmacist: focus on everolimus. Ann Pharmacother 2013; 47: 1055–63.
74. Herrero-Sanchez MC, Rodriguez-Serrano C, Almeida J, San-Segundo L, Inoges S, Santos-Briz A, et al. Effect of mTORC1/mTORC2 inhibition on T cell function: potential role in graft-versus-host disease control. Br J Haematol 2016; 173: 754–68.